Stryker won't make Mako surgical robots in China, CEO Kevin Lobo says, citing IP

Stryker chair and CEO Kevin Lobo said on Nov. 16 that the company has no plans to make any robots in China. "The IP is a massive worry," he said at the Fortune 500 Innovation Forum in Detroit, adding that Chinese companies "are knocking off a lot of the other robots." Stryker builds all of its orthopedic surgery robots in the U.S. and ships them worldwide, Fortune reported. Lobo said two of every three Stryker knee replacements now use its Mako robot, which he said has been used in 2.5 million procedures in 47 countries. He said one of Stryker's major competitors had bought into a Chinese robotics company, without naming it, and that Stryker does not see Chinese makers as an imminent threat. Stryker's roughly $400 million CMR Surgical deal is still subject to regulatory approvals.
Servospace take: Stryker's U.S. knee sales are nearly flat while U.S. Ortho Tech, which includes Mako, grew 18.1%
Servospace analysis: Stryker's own numbers show why Lobo is guarding the robot. In the third quarter, U.S. knee sales rose 1.3% to $458 million, while U.S. Ortho Tech sales rose 18.1% to $576 million, per its Oct. 29 earnings release, a gain ORTHOWORLD tied to Mako installations and upgrades, alongside strong demand for orthopedic power tools. Lobo also told analysts Mako sales "have been strong again this year" even as Stryker cut its 2026 organic growth forecast to 6.5% to 7%. The China threat he is pricing in is real: MicroPort MedBot said in June it had passed 300 global orders for its Toumai robot and could build up to 500 robots a year. Stryker's next bet is soft tissue, a market Lobo said has "only one big company," Intuitive Surgical. Versius, the CMR robot Stryker plans to sell in the U.S. as exclusive sales agent, has been used in more than 50,000 operations, about 2% of Mako's 2.5 million (Servospace arithmetic). Watch for regulators to clear the CMR deal and for which rival bought into a Chinese robot maker.
More on surgical robots.
Sources
- Fortune (Nov. 17, 2026): Stryker CEO Kevin Lobo says robots now do 2 of every 3 knee replacements, and he won't build them in China (Fortune 500 Innovation Forum, Detroit, Nov. 16; Mako 2.5 million procedures in 47 countries; MicroPort MedBot 300 orders, 500 robots a year)
- Stryker Q3 2026 earnings release, SEC Exhibit 99.1 (Oct. 29, 2026): U.S. knees $458 million, up 1.3%; U.S. Ortho Tech $576 million, up 18.1%; 2026 organic growth guidance 6.5% to 7.0%
- ORTHOWORLD (Oct. 2026): Stryker's joint replacement growth slows as Mako and shoulders show strength (Mako installations and upgrades supporting 18% organic U.S. Ortho Tech growth alongside orthopedic power tools)
- Stryker (Oct. 12, 2026): Stryker and CMR Surgical announce strategic alliance (about $400 million preferred equity, option to buy 100%, exclusive U.S. sales agent for Versius, subject to regulatory approvals)
- Cambridge Innovation Capital (Oct. 12, 2026): Versius used in more than 50,000 operations in more than 35 countries
New to robots? Read our guide: How robots work: a beginner's guide.
Summarized by Servospace from the sources above, drafted with AI help and checked against those sources before publishing. Claims are the companies' or outlets' unless we say otherwise. How we work.